1.Changes and signifieance of serum Heat Shock Proteins 70 in trauma shock patients
Zuowen YIN ; Bing LI ; Zhongjiang ZHAO
Journal of Clinical Surgery 2001;0(02):-
Objective In order to study the level chang e of HSP70 in trauma shock patients as well as to explore the relationship betwe en HSP70 and pathogenesis of trauma shock.Methods Serum HS P70 level in 30 healthy volunteers (rved as normal controls) and 36 trauma shock patients were measured by western blot. Results HSP70 was (4301.3?1155.3) in trauma shock group, 6092.3?1233.5 in the control group, and there was significance divination (P
2.Changes and roles of plasma p-selectin, vascular endothelial growth factor and nitricoxide in patients with traumatic shock
Zuowen YIN ; Bing LI ; Zhongjiang ZHAO
Journal of Clinical Surgery 2001;0(04):-
Objective To detect the role of P-Selectin(P-Sel), vascular endothelial growth factor(VEGF) and nitric oxide(NO) on the etiology of traumatic shock.Methods The levels of plasma P-Sel and VEGF in 43 cases traumatic shock patients and 30 normal controls were measured by means of enzyme linked immuno -sorbent assay (ELISA) and that of No was measured by colorimeteric method.Results (1) The plasma levels of P-Sel, VEGF and NO in patients with traumatic shock were much higher than those in the control (all P
3.Advances in immunosuppressive receptor LILRB4 in tumors and inflammatory diseases
Jingyi CHEN ; Yiliu LIU ; RUKEYA·Tu'erxunjiang ; Rui DING ; Jinping YIN ; Zuowen LIANG ; Jia ZHAO ; Jing LI
Chinese Journal of Immunology 2024;40(7):1559-1564
The leukocyte immunoglobulin-like receptor LILRB4(ILT3 or CD85k),a member of the immunosuppressive re-ceptor family,is expressed predominantly on the cell membranes of immune cells of myeloid origin,and exerts an immunosuppressive effect in immune regulation by activating either the autoinhibitory motif(ITIM)or by inhibiting Fc receptor activation motif(ITAM).In tumors,activation of LILRB4 receptor generates an immunosuppressive tumor microenvironment that assists in tumor invasion and metastasis,and in inflammatory diseases,LILRB4 is expressed on a variety of cells,such as monocytes,macrophages,mast cells,etc.,and attenuates inflammatory responses.Currently,LILRB4 has become a therapeutic target for tumors and various inflammatory diseases,and anti-LILRB4 monoclonal antibodies against acute myeloid leukemia(AML)have entered clinical trials.This review dis-cusses LILRB4 in terms of its structural distribution,signaling,therapeutic targets,and new drug development.